welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Tucson drug startup launches gastric-cancer trial
Tucson-based drug startup Cancer Prevention Pharmaceuticals Inc. has announced the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to test the company’s flagship drug candidate for preventing gastric cancer.
The drug, CPP-1X, will be studied in patients with precancerous gastric lesions who are at high risk for gastric cancer, the company said Monday.
The trial is funded by the National Cancer Institute and run in collaboration with gastroenterologists Dr. Keith T. Wilson and Dr. Douglas R. Morgan of the Vanderbilt University School of Medicine and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
- Clinical End Points for Developing Pharmaceuticals to Manage Patients with a Sporadic or Genetic Risk of Colorectal ...To reduce the morbidity and mortality fr...
- Invisible: How Young Women with Serious Health Issues Navigate Work, Relationships, and the Pressure to Seem Just Fi...Already appearing on must-read lists for...
- Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal CancerExecutive Summary Colorectal Cancer con...
- The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized C...Familial adenomatous polyposis (FAP) lea...
- Laparoscopic Total Colectomy (TPC) for Familial Adenomatous Polyposis – A Case ReportA 30-year-old man was admitted with anem...
- Huntsman Cancer Institute study delves into reasons why preventive drug is effectiveA potent preventive treatment for people...
- Cell Proliferation and Apoptotic Indices Predict Adenoma Regression in a Placebo-Controlled Trial of Celecoxib in Fa...BACKGROUND : Celecoxib was shown to regr...
English
Portuguese
Spanish